O'Reilly Automotive, Inc. · ORLY · FY2026 Q1 · Calendar Q2 2026
ORLY Q1 2026: Comp Sales Surge 8.1%, EPS Guidance Raised on Broad-Based Demand
O'Reilly Automotive's Q1 2026 results marked a sharp acceleration from its full-year 2025 pace, with comparable store sales of 8.1% well above the 3-5% full-year guide and a 14% increase in operating profit. Both DIY and professional segments contributed, aided by tax refunds and favorable weather that management estimates added 200-300 basis points of demand. The company raised full-year EPS guidance to $3.15-$3.25 from $3.10-$3.20 while maintaining its comp-sales, revenue, and margin outlook -- a signal that management views the strength as sustainable rather than a one-quarter pull-forward. The stock's 12.6% post-earnings drift lower, however, suggests the market remains cautious on whether that strength will persist through the remainder of 2026.
Company context
Snapshot as of publicationO'Reilly Automotive, Inc., along with its subsidiary companies, functions as a leading retail and wholesale provider of automotive aftermarket products, specialized tools, supplies, and accessories across the United States. The company's comprehensive inventory includes both new and reconditioned vehicle hard parts and essential maintenance items. This expansive selection covers critical components such as alternators, batteries, brake system parts, belts, chassis and driveline components, engine parts, fuel pumps, hoses, starters, temperature control systems, and water pumps. Additionally, they supply consumables like antifreeze, appearance products, engine additives, filters, various fluids, lighting solutions, oil, and wiper blades. Their accessory range features items like floor mats, seat covers, and specific truck enhancements. Beyond just parts, O'Reilly's outlets also stock auto body paint and related materials, a wide array of automotive tools, and specialized equipment catering to professional service providers.…
Earnings scorecard
Reported versus consensusEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| DA Davidson | Buy | Buy | Maintain | Jul 22, 2026 |
| Mizuho | Outperform | Outperform | Maintain | May 8, 2026 |
| UBS | Buy | Buy | Maintain | May 1, 2026 |
| TD Cowen | Buy | Buy | Maintain | May 1, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 1, 2026 |
| Citigroup | Buy | Buy | Maintain | May 1, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Apr 30, 2026 |
| Truist Securities | Buy | Buy | Maintain | Feb 6, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Feb 6, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Feb 6, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jan 15, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Oct 27, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 24, 2025 |
| Guggenheim | Buy | Buy | Maintain | Jul 25, 2025 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 25, 2025 |
| Wedbush | Neutral | Neutral | Maintain | Feb 6, 2025 |
| B of A Securities | Buy | Buy | Maintain | Aug 22, 2024 |
| Stephens & Co. | Overweight | Overweight | Maintain | Dec 19, 2023 |
| Oppenheimer | Perform | Outperform | Downgrade | Oct 6, 2023 |
| Roth MKM | Buy | Buy | Maintain | May 12, 2023 |
| MKM Partners | Buy | Buy | Maintain | Jun 23, 2022 |
| Raymond James | Market Perform | Outperform | Downgrade | Jul 27, 2021 |
| Nomura Instinet | Neutral | Neutral | Maintain | May 20, 2020 |
| Nomura | Neutral | Neutral | Maintain | May 20, 2020 |
| Atlantic Equities | Underweight | Neutral | Downgrade | Jan 23, 2020 |
| Credit Suisse | Neutral | Neutral | Maintain | Oct 25, 2019 |
| Northcoast Research | Neutral | Buy | Downgrade | Jun 27, 2019 |
| Jefferies | Buy | Buy | Maintain | Oct 26, 2018 |
| Bank of America | Buy | Buy | Maintain | Sep 17, 2018 |
| MoffettNathanson | Neutral | Buy | Downgrade | Jun 25, 2018 |
| Moffett Nathanson | Neutral | Buy | Downgrade | Jun 25, 2018 |
| Baird | Neutral | Neutral | Maintain | Feb 9, 2018 |
| Susquehanna | Neutral | Positive | Downgrade | Jun 20, 2017 |
| Deutsche Bank | Hold | Buy | Downgrade | Apr 25, 2017 |
| Cleveland Research | Neutral | Buy | Downgrade | Apr 3, 2017 |
| BTIG Research | Buy | Buy | Maintain | Jun 1, 2016 |
| Gabelli & Co. | Buy | Buy | Maintain | Apr 15, 2016 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Apr 12, 2016 |
| Sterne Agee CRT | Buy | Neutral | Upgrade | Jan 25, 2016 |
| Sterne Agee | Buy | Neutral | Upgrade | Jan 25, 2016 |
| Stifel Nicolaus | Hold | Buy | Downgrade | Jul 18, 2014 |
| Stifel | Hold | Buy | Downgrade | Jul 18, 2014 |
| PiperJaffray | Neutral | Overweight | Downgrade | Jan 7, 2013 |
| Piper Sandler | Neutral | Overweight | Downgrade | Jan 7, 2013 |
| Bank oferica | Buy | Buy | Maintain | Apr 26, 2012 |
| Morgan Keegan | Outperform | Outperform | Maintain | Feb 10, 2012 |
| Cabrera Capital Markets | Outperform | Outperform | Maintain | Feb 9, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $91.17. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Analyst unavailable | $100 | $86.11 | +9.7% | Jul 24, 2026 |
| D.A. Davidson | Michael Baker | $114 | $87.72 | +25.0% | Jul 22, 2026 |
| Wolfe Research | Analyst unavailable | $98 | $85.75 | +7.5% | Jul 15, 2026 |
| Goldman Sachs | Kate McShane | $113 | $87.28 | +23.9% | Jul 13, 2026 |
| Roth Capital | Analyst unavailable | $109 | $96.83 | +19.6% | May 4, 2026 |
| Robert W. Baird | Analyst unavailable | $110 | $98.71 | +20.7% | May 1, 2026 |
| Evercore ISI | Greg Melich | $115 | $99.19 | +26.1% | May 1, 2026 |
| Raymond James | Analyst unavailable | $115 | $98.69 | +26.1% | May 1, 2026 |
| Truist Financial | Analyst unavailable | $108 | $99.4 | +18.5% | Apr 30, 2026 |
| Morgan Stanley | Simeon Gutman | $112 | $97.58 | +22.8% | Apr 30, 2026 |
| Wells Fargo | Analyst unavailable | $110 | $91.69 | +20.7% | Apr 30, 2026 |
| Morgan Stanley | Analyst unavailable | $108 | $92.96 | +18.5% | Feb 9, 2026 |
| Truist Financial | Analyst unavailable | $107 | $92.3 | +17.4% | Feb 6, 2026 |
| Robert W. Baird | Analyst unavailable | $96 | $91.94 | +5.3% | Feb 6, 2026 |
| D.A. Davidson | Michael Baker | $110 | $92.08 | +20.7% | Feb 6, 2026 |
| RBC Capital | Steven Shemesh | $109 | $92.3 | +19.6% | Feb 6, 2026 |
| UBS | Analyst unavailable | $114 | $92.08 | +25.0% | Feb 6, 2026 |
| Mizuho Securities | Analyst unavailable | $105 | $92.86 | +15.2% | Feb 6, 2026 |
| RBC Capital | Steven Shemesh | $111 | $98.85 | +21.8% | Jan 30, 2026 |
| Morgan Stanley | Analyst unavailable | $110 | $95.02 | +20.7% | Jan 15, 2026 |
| Evercore ISI | Analyst unavailable | $110 | $94.31 | +20.7% | Dec 16, 2025 |
| Robert W. Baird | Analyst unavailable | $115 | $98.61 | +26.1% | Dec 3, 2025 |
| Raymond James | Bobby Griffin | $105 | $93.83 | +15.2% | Nov 5, 2025 |
| Barclays | Seth Sigman | $91 | $95.68 | -0.2% | Oct 27, 2025 |
| Truist Financial | Scot Ciccarelli | $109 | $98.12 | +19.6% | Oct 24, 2025 |
| RBC Capital | Steven Shemesh | $110 | $98.27 | +20.7% | Oct 24, 2025 |
| Goldman Sachs | Analyst unavailable | $121 | $98.27 | +32.7% | Oct 24, 2025 |
| Morgan Stanley | Simeon Gutman | $115 | $100 | +26.1% | Oct 23, 2025 |
| Mizuho Securities | Analyst unavailable | $112 | $101.6 | +22.8% | Oct 20, 2025 |
| UBS | Michael Lasser | $120 | $103.05 | +31.6% | Oct 15, 2025 |
| Wells Fargo | Analyst unavailable | $115 | $103.05 | +26.1% | Oct 15, 2025 |
| Wolfe Research | Analyst unavailable | $121 | $104.55 | +32.7% | Sep 17, 2025 |
| UBS | Michael Lasser | $1,580 | $1,352.17 | +1633.0% | Apr 24, 2025 |
| Truist Financial | Scot Ciccarelli | $1,290 | $1,187.53 | +1314.9% | Oct 14, 2024 |
| Wells Fargo | Zachary Fadem | $1,325 | $1,187.53 | +1353.3% | Oct 14, 2024 |
| Evercore ISI | Greg Melich | $1,230 | $1,138.16 | +1249.1% | Aug 22, 2024 |
| Jefferies | Bret Jordan | $1,260 | $1,110.31 | +1282.0% | Jul 26, 2024 |
| RBC Capital | Steven Shemesh | $1,115 | $1,117.06 | +1123.0% | Jul 26, 2024 |
| Truist Financial | Scot Ciccarelli | $1,204 | $1,092.91 | +1220.6% | Jul 25, 2024 |
| Truist Financial | Scot Ciccarelli | $1,143 | $1,016.32 | +1153.7% | Jul 2, 2024 |
| CFRA | Garrett Nelson | $1,100 | $921.64 | +1106.5% | Oct 26, 2023 |
| Barclays | Analyst unavailable | $815 | $801.02 | +793.9% | Feb 8, 2023 |
| Wells Fargo | Analyst unavailable | $925 | $830.21 | +914.6% | Jan 5, 2023 |
| Citigroup | Analyst unavailable | $855 | $851.38 | +837.8% | Nov 23, 2022 |
| D.A. Davidson | Mike Baker | $740 | $637.6 | +711.7% | Jun 29, 2022 |
| Morgan Stanley | Analyst unavailable | $650 | $618.48 | +613.0% | Apr 29, 2022 |
| RBC Capital | Analyst unavailable | $806 | $623.28 | +784.1% | Apr 29, 2022 |
| Wells Fargo | Zachary Fadem | $800 | $703.6 | +777.5% | Apr 25, 2022 |
| Citigroup | Steven Zaccone | $720 | $665.67 | +689.7% | Jan 18, 2022 |
| D.A. Davidson | Michael Baker | $700 | $701.77 | +667.8% | Dec 30, 2021 |
| Oppenheimer | Brian Nagel | $800 | $672 | +777.5% | Dec 9, 2021 |
| UBS | Michael Lasser | $720 | $638.33 | +689.7% | Oct 18, 2021 |
| Goldman Sachs | Kate McShane | $638 | $607.38 | +599.8% | Jul 20, 2021 |
| Credit Suisse | Lavesh Hemnani | $496 | $548.07 | +444.0% | May 18, 2021 |
Track every rating change on ORLY the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session closeFollow ORLY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Comparable store sales accelerated from 4.7% (full-year 2025) to 8.1% in Q1 2026, well above the 3-5% full-year guide. Operating profit growth reached 14% in Q1, up from 6.4% full-year 2025 growth. Full-year 2026 EPS guidance was raised to $3.15-$3.25 from the initial $3.10-$3.20. Private-label penetration crossed 50% of total revenue for the first time. Tax refunds and favorable weather together added an estimated 200-300 bps of Q1 demand. Share repurchases totaled 10 million shares for $923 million in Q1.
Guidance delta
Full-year 2026 EPS guidance raised to $3.15-$3.25 from $3.10-$3.20. Revenue ($18.7-$19B), comparable store sales (3-5%), gross margin (51.5-52%), and capex ($1.3-$1.4B) all maintained.
Key takeaways
- Comparable store sales rose 8.1% with total sales up 10.2%, beating consensus revenue estimates by 2.3%.
- EPS of $0.72 beat the $0.695 consensus by 3.6%.
- Operating profit grew 14%, reflecting leverage on higher sales and stable gross margins above 51%.
- Private-label products now exceed 50% of total revenue, supporting margin resilience.
- Full-year EPS guidance raised to $3.15-$3.25; all other guidance metrics maintained.
- Share repurchases returned $923 million to shareholders in the quarter.
Management priorities
- Open 225-235 net new stores in 2026 across the U.S., Mexico, and Canada.
- Invest $1.3-$1.4 billion in capital projects, including distribution expansion and store infrastructure.
- Continue growing private-label penetration to drive margin improvement and brand loyalty.
- Maintain the share repurchase program to return excess capital to shareholders.
- Expand distribution network, including the Virginia DC and preparation of the Fort Worth DC for 2028.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-29T11:51:38.672084+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-29T11:51:38.668781+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.